Related Experiment Videos
Microbiome Targeted Therapies for Primary Sclerosing Cholangitis
Matthew Carson1,2,3, Vik Meadows1,2,4, Kari Nejak-Bowen1,2,4
1University of Pittsburgh School of Medicine, Organ Pathobiology and Therapeutics Institute, Pennsylvania, United States, Pittsburgh.
Abstract:
Primary sclerosing cholangitis is a rare, progressive cholestatic liver disease of the intrahepatic and extrahepatic bile ducts with poor prognosis. The only life-extending treatment for PSC is liver transplantation, with up to 25% of post-transplant patients developing recurrent disease, highlighting an extrahepatic influence on disease. The gut-liver axis has been widely studied in the development and pathogenesis of PSC, with preclinical and clinical work demonstrating that targeting gut microbiota and its metabolites can elicit therapeutic effects against PSC. This review describes various microbiome-based therapeutics and their effectiveness in treating PSC, including antibiotics, probiotics, fecal microbiota transplantation, and bacteriophages. In conclusion, the use of microbiota-derived metabolites as potential therapeutics is also addressed.
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Microbiota Modulation by Antibiotics
Targeted Cancer Therapies
There are several types of targeted therapies against specific...